



Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from <https://aidsinfo.nih.gov/guidelines> on 9/13/2019

Visit the *AIDSinfo* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <https://aidsinfo.nih.gov/e-news>.

Table 15i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
 (Last updated April 16, 2019; last reviewed April 16, 2019) (page 1 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
Urolithiasis/ Nephrolithiasis	ATV DRV causes crystalluria, but it is not associated with nephrolithiasis.	<u>Onset:</u> <ul style="list-style-type: none"> • Weeks to months after starting therapy <u>Clinical Findings:</u> <ul style="list-style-type: none"> • Crystalluria • Hematuria • Pyuria • Flank pain • Increased creatinine in some cases 	ATV-related nephrolithiasis occurs in <10% of patients.	In adults, elevated urine pH (>5.7) The risk factors in children are unknown.	<u>Prevention:</u> <ul style="list-style-type: none"> • Maintain adequate hydration. <u>Monitoring:</u> <ul style="list-style-type: none"> • Obtain urinalysis at least every 6 months–12 months. 	Provide adequate hydration and pain control. Consider using another ARV in place of ATV.
Renal Dysfunction	TDF	<u>Onset:</u> <ul style="list-style-type: none"> • Variable; in adults, renal dysfunction may occur weeks to months after initiating therapy. • Hypophosphatemia appears at a median of 18 months. • Glucosuria may occur after a year of therapy. • Abnormal urine protein/osmolality ratio may be an early indicator. <u>Presentation</u> <i>More Common:</i> <ul style="list-style-type: none"> • Increased serum creatinine, proteinuria, normoglycemic glucosuria • Increased urinary protein/creatinine ratio and albumin/creatinine ratio • Hypophosphatemia, usually asymptomatic; may present with bone and muscle pain, or muscle weakness <i>Less Common:</i> <ul style="list-style-type: none"> • Renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus with polyuria 	<u>Adults:</u> <ul style="list-style-type: none"> • Approximately 2% experience increased serum creatinine levels. • Approximately 0.5% experience severe renal complications <u>Children:</u> <ul style="list-style-type: none"> • Approximately 4% experience hypophosphatemia or proximal tubulopathy; frequency increases with prolonged TDF therapy and advanced HIV infection. 	<u>Risk May Increase in Children with the Following Characteristics:</u> <ul style="list-style-type: none"> • Aged >6 years • Black race, Hispanic/Latino ethnicity • Advanced HIV infection • Hypertension • Diabetes • Concurrent use of PIs (especially LPV/r) and preexisting renal dysfunction • Risk increases with longer duration of TDF treatment. 	Monitor urine protein, urine glucose and serum creatinine at 3-month to 6-month intervals. For patients taking TDF, some Panel members routinely monitor serum phosphate levels. Measure serum phosphate if the patient experiences persistent proteinuria or glucosuria, or has symptoms of bone pain, muscle pain, or weakness. Because toxicity risk increases with the duration of TDF treatment, do not decrease the frequency of monitoring over time.	If TDF is the likely cause, consider using an alternative ARV drug. TAF has significantly less toxicity than TDF.

Table 15i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
 (Last updated April 16, 2019; last reviewed April 16, 2019) (page 2 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
Elevation in Serum Creatinine	DTG, COBI, RPV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> • Within a month of starting treatment <p><u>Presentation:</u></p> <ul style="list-style-type: none"> • Asymptomatic. These drugs decrease renal tubular secretion of creatinine, leading to an increase in serum creatinine levels without a true change in eGFR. 	<p>Common</p> <p>Need to distinguish between a true change in eGFR and other causes. A true change may be associated with other medical conditions, the continuing rise of serum creatinine levels over time, and albuminuria.</p>	N/A	Monitor serum creatinine. Assess for renal dysfunction if serum creatinine increases by >0.4 mg/dL or if increases continue over time.	<p>No need to change therapy.</p> <p>Reassure the patient about the benign nature of the laboratory abnormality.</p>

Key to Acronyms: ARV = antiretroviral; ATV = atazanavir; COBI = cobicistat; **dL = deciliter**; DRV = darunavir; DTG = dolutegravir; eGFR = estimated glomerular filtration rate; LPV/r = lopinavir/ritonavir; PI = protease inhibitor; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

References

1. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. *Pediatr Infect Dis J.* 2009;28(7):619-625. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19561425>.
2. Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. *AIDS.* 2010;24(4):525-534. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20139752>.
3. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. *Arch Pediatr Adolesc Med.* 2009;163(2):164-171. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19188649>.
4. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. *Pediatr Infect Dis J.* 2009;28(3):204-209. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19209091>.
5. Soler-Palacin P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. *AIDS.* 2011;25(2):171-176. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21076275>.
6. van Rossum AM, Dieleman JP, Fraaij PL, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. *AIDS.* 2001;15(13):1745-1747. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11546957>.
7. van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. *Pediatrics.* 2002;110(2 Pt 1):e19. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12165618>.
8. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. *Am J Kid Dis.* 2011;57(5):773-780. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21435764>.

9. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. *Clin Infect Dis*. 2010;51(5):496-505. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20673002>.
10. Vigano A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. *Clin Drug Investig*. 2011;31(6):407-415. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21528939>.
11. Fraaij PL, Verweel G, van Rossum AM, Hartwig NG, Burger DM, de Groot R. Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment. *Infection*. 2007;35(3):186-189. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17565462>.
12. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. *Pediatr Infect Dis J*. 2013;32(5):495-500. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23249917>.
13. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. *PLoS One*. 2013;8(10):e77268. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24130871>.
14. de Lastours V, Ferrari Rafael De Silva E, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. *J Antimicrob Chemother*. 2013;68(8):1850-1856. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23599359>.
15. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. *J Acquir Immune Defic Syndr*. 2012;61(1):32-40. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22732469>.
16. Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. *AIDS*. 2014;28(5):621-632. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24983540>.
17. Lim Y, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally-acquired HIV infection: a single-centre cohort study. *Clin Drug Investig*. 2015;35(5):327-333. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25861908>.
18. Samarawickrama A, Cai M, Smith ER, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. *HIV Med*. 2012;13(9):526-532. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22413854>.
19. Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA. Is abnormal urine protein/osmolality ratio associated with abnormal renal function in patients receiving tenofovir disoproxil fumarate? *PLoS One*. 2016;11(2):e0149562. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26872144>.
20. Lin KY, Liao SH, Liu WC, et al. Cholelithiasis and nephrolithiasis in HIV-positive patients in the era of combination antiretroviral therapy. *PLoS One*. 2015;10(9):e0137660. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26360703>.
21. Bunupuradah T, Phupitakphol T, Sophonphan J, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai adolescents. *Pediatr Infect Dis J*. 2017. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28719505>.
22. Purswani MU, Patel K, Winkler CA, et al. Brief Report: APOL1 Renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. *J Acquir Immune Defic Syndr*. 2016;73(1):63-68. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27035887>.
23. Soares DS, Cavalcante MG, Ribeiro SM, et al. Acute kidney injury in HIV-infected children: comparison of patients according to the use of highly active antiretroviral therapy. *J Pediatr (Rio J)*. 2016;92(6):631-637. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27542916>.
24. Melvin AJ, Warshaw M, Compagnucci A, et al. Hepatic, renal, hematologic, and inflammatory markers in HIV-infected children on long-term suppressive antiretroviral therapy. *J Pediatric Infect Dis Soc*. 2017;6(3):e109-e115. Available at <https://www.ncbi.nlm.nih.gov/pubmed/3979993>.
25. Unsal AB, Mattingly AS, Jones SE, et al. Effect of Antiretroviral therapy on bone and renal health in young adults with HIV in early life. *J Clin Endocrinol Metab*. 2017;102(8):2896-2904. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28531309>.